ITMN : IterMune Biopharmaceuticals gets good news from the FDA

ITMN's drugs are currently under FDA review. Image from Flickr.

This morning, IterMune stocks (on the New York Stock Exchange as ITMN) rose over 60%. This was a result of the FDA annoucing it would be reviewing ITMN's drug application for their new drug Esbriet (pirfenidone). The FDA has expressed concerns over this particular drug, however, so I wouldn't yet recommend taking out personal installment loans just to buy this stock - at least, not yet.

ITMN drug treats lung problems

The new drug from ITMN that the FDA will be reviewing is intended to treat idiopathic pulmonary fibrosis. This is a condition where a person's lungs (pulmonary system) develops thick, heavy scarring (fibrosis). Idiopathic cases are simply cases that have no known cause. Learn more about the disease ITMN's new drug is intended to treat on the Mayo Clinic website or on Google Health. If the drug ITMN developed is approved, it would be the first and only treatment intended for this deadly disease. ... click here to read the rest of the article titled "ITMN : IterMune Biopharmaceuticals gets good news from the FDA"